Gefitnib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 1873-1877

  Gridelli, Cesare ^a   Rossi, Antonio ^a   Maione, Paolo ^a   Guerriero, Ciro ^a   Airoma, Giuseppe ^a   Colantuoni, Giuseppe ^a   Barzelloni, Maria Luisa ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Gefitinib; NSCLC; Salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; DIARRHEA; DRUG ACTIVITY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NAIL DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SKIN TOXICITY; LUNG TUMOR; MIDDLE AGED; PATIENT COMPLIANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUINAZOLINES; SALVAGE THERAPY;

EID: 3242679037     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Maxwell PD: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Jemal A, Thomas A, Murray T and Thun M: Cancer Statistics 2002. CA Cancer J Clin 52: 23-47, 2002.
3. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899-909, 1995.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
5. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L and Tonato M: Phase III randomized trial comparing three platinum-basd doublets in advanced non-small-cell lung cancer. J Clin Oncol 20: 4285-4291, 2002.
6. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M and Belani CP: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024, 2003.
7. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P and Vlachonikolis I: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357: 1478-1484, 2001.
8. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N and Giaccone G: A phase III trial of European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21: 3909-3917, 2003.
9. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L and Perrone F: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21: 3025-3034, 2003.
10. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y and Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2085-2103, 2000.
11. Ciardiello F and Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958-2970, 2001.
12. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J and LoRusso PM: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20: 3815-3825, 2002.
13. Giaccone G, Johnson DH, Manegold C, Scagliotti GV, Rosell R, Wolf M, Rennie P, Ochs J, Averbuch S and Fandi A: A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 13: 2 (abstr. 40), 2002.
14. Johnson DH, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, Wolf M, Helton A, Averbuch S and Grous J: ZD1839 (Iressa) in combination with paclitaxel & carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): Results from a phase III clinical trial (INTACT 2). Ann Oncol 13: 127 (abstr. 4680), 2002.
15. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246, 2003.
16. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003.
17. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-14, 1981.
18. Green MR, Cox JD, Ardizzoni A, Arriagada R, Burau G, Darwish S, Deneffe G, Fukuoka M, Joseph D and Komaki R: Endpoints for multimodal clinical trials in stage III non-small cell lung cancer: A consensus report. Lung Cancer 11(suppl 3): S11-S13, 1994.
19. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F and Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with non-small cell lung cancer previously treated with platinum - containing chemotherapy regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group. J Clin Oncol 18: 2354-2362, 2000.
20. Hanna NH, Shepherd FA, Rosell R, Pereira JR, De Marinis F, Fossella F, Kayitalire L, Paul S, Einhorn LH and Bunn PA: A phase III study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc Am Soc Clin Oncol 22: 622 (abstr. 2503), 2003.
21. Gridelli C, Maione P, Colantuoni G and Rossi A: Chemotherapy of non-small cell lung cancer in elderly patients. Cur Med Chem 9: 1487-1495, 2002.
22. Bunn PA Jr.: Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20(18 Suppl): 23S-33S, 2002.